Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management

Launched by CENTRE FRANCOIS BACLESSE · May 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of adapted aesthetic support for patients with cancers in the upper aerodigestive tract, which includes areas like the throat, mouth, and nasal cavity. The aim is to understand how this support can help patients cope with the physical and emotional impacts of their cancer treatment. Many patients have shared positive experiences with this type of support, and the study will look at how well it works and any challenges that might arise during the process.

To participate in this trial, you need to be at least 18 years old and diagnosed with cancer in one of the specified areas. You should also be starting treatment aimed at curing your cancer and be fluent in French. It's important to know that the study is not currently recruiting participants, but it will take a closer look at how oncoesthetics can help improve the quality of life for patients facing these challenging diagnoses. If you decide to take part, you will receive tailored support designed to help with both your physical appearance and emotional well-being during treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient aged 18 or over
• • Neoplastic location: oropharynx, oral cavity, hypopharynx, larynx, nasal cavity, salivary glands, cavum, sinus.
• • Patient due to start oncological treatment (recurrence authorized)
• • Patient fluent in French.
• • Affiliation with a social security scheme
• • Signature of informed consent prior to any specific procedure linked to the study
• • Treatment with curative intent
• Exclusion Criteria:
• • Breast-feeding or pregnant patient
• • Any associated medical or psychological condition that could compromise the patient's ability to participate in the study
• • Patient deprived of liberty, under guardianship, or subject to a legal protection measure or unable to express their consent.
• • Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons.